Amgen (WBO:AMGN) Gross-Profit-to-Asset % : 21.44% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Amgen Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Amgen's annualized Gross Profit for the quarter that ended in Dec. 2023 was €18,648 Mil. Amgen's average Total Assets over the quarter that ended in Dec. 2023 was €86,960 Mil. Therefore, Amgen's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 21.44%.

Amgen Gross-Profit-to-Asset % Historical Data

The historical data trend for Amgen's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Gross-Profit-to-Asset % Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

30.51

30.03

32.64

32.53

24.04

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															30.57	22.70	22.99	22.72	21.44

Competitive Comparison of Amgen's Gross-Profit-to-Asset %

For the Drug Manufacturers - General subindustry, Amgen's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Amgen's Gross-Profit-to-Asset % falls into.

Amgen Gross-Profit-to-Asset % Calculation

Amgen's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	18100.663	/	( (61474.224	+	89090.218)	/ 2 )
	=	18100.663	/	75282.221
	=	24.04 %

Amgen's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	18648.112	/	( (84830.358	+	89090.218)	/ 2 )
	=	18648.112	/	86960.288
	=	21.44 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Amgen Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Amgen's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (WBO:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (WBO:AMGN) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.